[DOI] [PMC free article] [PubMed] [Google Scholar] 115.Kong L., Deng J., Zhou X., Cai B., Zhang B., Chen X., Chen Z., Wang W
20, 208211, 10.1089/acm.2012.0612 [DOI] [PubMed] [Google Scholar] 86.Wilson R.B
53 Another recent, randomized, multicenter, open-label trial was conducted in the UK and studied whether targeting an albumin serum level 30 g/L would reduce the risk of infections, renal dysfunction and death in patients with decompensated cirrhosis
Still investigational: not FDA-approved, and patient counseling must reflect this
Obeticholic acid has shown promising results in improving BAD symptoms (9) but due to safety concerns (12) and lack of efficacy (13) in patients with primary biliary cholangitis, its use has been significantly restricted
Gastroenterology 2023;165(2):499501.e4